icotec has won a Medicare New Technology Add-On Payment for CMORE CT, its nonmetallic posterior cervicothoracic spine stabilization system, closing a gap that often slows hospital adoption of newly cleared hardware: the cost of a device priced above what a standard Medicare case payment covers. The Swiss company announced the approval on 6 October 2026, effective from 1 October 2026 under the FY2027 Medicare inpatient payment rules.
Carbon fiber where titanium used to be
icotec has spent its history on a narrow bet: that spine hardware built from continuous carbon-fiber-reinforced PEEK, rather than titanium, is worth the switch. Its BlackArmor material process — the company calls it Injection Molding CFM, for Composite Flow Molding — produces polyaxial screws, rods and connectors with roughly a 55% fiber volume fraction, manufactured under the company’s own FDA Material Master File. CMORE CT applies that material to a new region: posterior stabilization of the cervicothoracic spine, the transition zone between neck and upper back.
The pitch to surgeons is imaging, not strength alone. A titanium pedicle screw scatters X-rays and distorts CT and MRI images around the fixation site, which can mask recurrent disease or complicate follow-up imaging in cancer and trauma patients. icotec’s own factsheet describes BlackArmor hardware as radiolucent across all three major imaging modes, with a titanium coating (Ti-iT) applied only where the screw meets bone, for fixation rather than imaging.
Three things CMS and FDA both signed off on
Nonmetallic, imaging-clear
BlackArmor's carbon/PEEK construction is designed to leave CT, MRI and X-ray images largely free of the metal artifact a titanium construct produces at the fixation site — the clinical case icotec has built its hardware line around.
A Breakthrough-track review
FDA granted CMORE CT Breakthrough Device Designation in April 2025, ahead of its November 2025 510(k) clearance for the cervicothoracic indication — the expedited-interaction track reserved for devices addressing an unmet need.
A Medicare payment secured
The October 2026 NTAP decision gives hospitals a specific, calculable add-on rather than an open-ended cost, the detail that most often decides whether a newly cleared device clears a hospital's value-analysis committee.
CMORE CT's add-on, in four figures
Figures from CMS's New Technology Add-On Payment decision and icotec's 6 October 2026 announcement.
“We are thrilled that CMS has recognized our new CMORE® CT System through the NTAP program.” Christoph Eigenmann, CEO, icotec USA — 6 October 2026 announcement
The gap a reimbursement code closes
A device clearing FDA review is only half of a hospital’s decision. Medicare pays hospitals a fixed amount per diagnosis-related group (DRG) regardless of which implant a surgeon chooses, so a pricier new device can simply cost the hospital margin unless a separate payment recognizes it. CMS’s New Technology Add-On Payment program exists for exactly that gap: a temporary, case-by-case supplement — capped at the lesser of 65% of the technology’s cost or 65% of the amount the case’s cost exceeds the standard DRG payment — for devices CMS judges to offer a substantial clinical improvement over existing alternatives.
CMS set CMORE CT’s cap using an average technology cost of $93,700, producing the $60,905 maximum. icotec is not the first spine-implant maker to use the pathway: Carlsmed’s patient-specific aprevo system holds its own NTAP for lumbar and cervical fusion procedures, on a 3D-printed titanium platform rather than a nonmetallic one. The two companies are solving the same adoption problem from different materials.
Ten billion dollars still priced in titanium
Spinal fixation and fusion hardware is a mature, multibillion-dollar category built almost entirely around titanium and, more recently, PEEK cages — led by Medtronic, Stryker, Zimmer Biomet, NuVasive and Globus Medical. BlackArmor is a narrower bet within that category: a fully nonmetallic construct for the posterior elements themselves, not just the interbody cage, sold on imaging clarity rather than strength or price.
The fixation hardware market CMORE CT enters
$8.27B → $12.99B
Global spinal fusion devices market, 2022 to 2030, as reported by Insight Partners (via ODT Magazine); Allied Market Research’s separate 2030 estimate is shown for comparison.
Sources: Insight Partners spinal fusion devices forecast, via ODT Magazine, January 2024 · Allied Market Research, Spinal Fusion Devices Market
Regulatory News outlook
We expect nonmetallic, imaging-compatible fixation hardware to remain a small but growing slice of the roughly $10–13 billion spinal-fixation market through 2030, with Medicare reimbursement now doing more than FDA clearance to decide how fast it spreads.
How we got here: Compounding Insight Partners' $8.27 billion 2022 figure at its own reported 5.8% rate reaches $12.99 billion by 2030; we treat nonmetallic constructs as a low-single-digit share of that total, since icotec's NTAP covers one indication within a market still dominated by titanium hardware.
CMORE CT against the hardware already in the OR
| Product | Material | Imaging profile | Reimbursement | Approach |
|---|---|---|---|---|
| CMORE CT (icotec) | Carbon-fiber-reinforced PEEK (BlackArmor), nonmetallic | Radiolucent; designed for low-artifact CT/MRI/X-ray | CMS NTAP, up to $60,905/case (eff. Oct 2026) | Standardized implant line |
| aprevo (Carlsmed) | 3D-printed titanium | Standard titanium imaging artifact | CMS NTAP, cervical and lumbar fusion (separate decisions) | Patient-specific, CT/MRI-planned |
| Conventional titanium posterior systems | Titanium alloy | Imaging artifact at the screw and rod | Included in the standard DRG payment; no add-on | Off-the-shelf |
From each company's own labelling and announcements, and CMS's published NTAP decisions; not a clinical comparison.
From a US CEO hire to a Medicare code
icotec's road to a Medicare payment code
- February 2024
A dedicated US CEO
icotec appointed Christoph Eigenmann as CEO of icotec USA and promoted Carter Lonsberry to Executive Chairman of the Board, ahead of the company's planned US commercial push.
- April 2025
Breakthrough Device Designation
FDA granted CMORE CT Breakthrough Device Designation, putting it on the agency's expedited-interaction track.
- November 2025
FDA 510(k) clearance
FDA cleared CMORE CT for posterior stabilization of the cervicothoracic spine.
- 5 December 2025
AO Technical Commission approval
The AO Technical Commission Spine group approved the system, with US market release targeted for the first quarter of 2026.
- 1 October 2026
CMS NTAP takes effect
The New Technology Add-On Payment became effective for qualifying Medicare cases, announced by icotec on 6 October 2026.
- Through FY2027
The reimbursement window
NTAP status is temporary by design, typically running two to three federal fiscal years before CMS revisits the technology's cost and adoption.
What a payment code doesn't settle
An add-on payment removes a hospital's cost objection; it does not, on its own, change what a surgeon chooses in the operating room. icotec's own case for BlackArmor — cleaner post-operative imaging, particularly for patients who will need repeat CT or MRI surveillance — is a radiology and oncology argument as much as a spine-surgery one, and the company has not published comparative outcome data against titanium constructs in the cervicothoracic indication specifically.
- Scope: the NTAP decision applies to specified spinal conditions and procedures in the cervicothoracic region; it is not a blanket payment for every use of icotec's hardware.
- Case-by-case: CMS calculates the add-on per case against the actual cost difference, capped at $60,905; a hospital is not guaranteed the maximum on every qualifying patient.
- Not yet public: icotec has not disclosed US sales volumes or hospital-count adoption figures for CMORE CT since its Q1 2026 targeted release.
Sources & further reading
- icotec, “icotec Receives CMS Approval for New Technology Add-On Payment for its CMORE® CT System,” press release, 6 October 2026. prnewswire.com
- Becker's Spine Review, “CMS approves Medicare payment boost for spine implant,” 2026. beckersspine.com
- OrthoWorld, “icotec CMORE CT Gains Approval for Medicare NTAP.” orthoworld.com
- icotec, “icotec Receives FDA Clearance for the CMORE® CT System, Expanding its BlackArmor® Engineered Carbon/PEEK Technology to the Posterior Cervicothoracic Spine,” press release, 13 November 2025. newswire.ca
- OrthoWorld, “icotec Gains FDA Clearance for CMORE CT System.” orthoworld.com
- AO Foundation, “CMORE® Cervicothoracic System,” AO Technical Commission approval record, December 2025. aofoundation.org
- BioSpace, “icotec Medical Appoints Christoph Eigenmann as New US CEO and Promotes Carter Lonsberry to Executive Chairman of the Board,” February 2024. biospace.com
- ODT Magazine, “Solid Growth Predicted for Spinal Fusion Devices Market,” January 2024 (citing Insight Partners). odtmag.com
- Allied Market Research, “Spinal Fusion Devices Market.” alliedmarketresearch.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did CMS approve for icotec?
A New Technology Add-On Payment (NTAP) for the CMORE CT System, effective 1 October 2026. Eligible hospitals can receive up to $60,905 per qualifying inpatient Medicare case, on top of the standard DRG payment, when the device is used for specified cervicothoracic spine procedures.
Is the payment guaranteed every time the implant is used?
No. CMS calculates the add-on case by case, capped at the lesser of 65% of the device's cost or 65% of the amount by which the case's cost exceeds the standard DRG payment. It is not a flat bonus for every procedure.
What is CMORE CT made of?
BlackArmor, icotec's continuous carbon-fiber-reinforced PEEK composite. The implant is nonmetallic and radiolucent, intended to leave CT, MRI and X-ray images largely free of the metal artifact that titanium hardware can cause at the fixation site.
When was CMORE CT cleared by FDA?
FDA cleared the system for posterior cervicothoracic spine stabilization in November 2025, after granting it Breakthrough Device Designation in April 2025. The AO Technical Commission Spine group separately approved it on 5 December 2025.
